What is the Perseus Proteomics Inc. stock price forecast?

Perseus Proteomics Inc. is currently trading at ¥143. View real-time AI analysis on Alpha Lenz.

What is Perseus Proteomics Inc. insider trading activity?

View the latest insider trading data for Perseus Proteomics Inc. on Alpha Lenz.

What is Perseus Proteomics Inc.'s P/E ratio?

Perseus Proteomics Inc.'s P/E ratio is -2.3.

Perseus Proteomics Inc.

JPX · 4882

¥143-3(-2.05%)Market closed

Ask about Perseus Proteomics Inc.'s future dividend policy...

Alpha Chat Insight

“Perseus Proteomics Inc. trades at a P/E of -2.3 (undervalued) with modest ROE of -63.9%. 3Y revenue CAGR of 18.7% highlights clear growth momentum.”

Ask for details →

Company Overview

Perseus Proteomics Inc. is a biotechnology company that focuses on the research and development of therapeutic antibodies. The primary purpose of the company is to explore innovative solutions for unmet medical needs, harnessing the potential of proteomics to develop targeted therapies. Perseus Proteomics operates within the healthcare sector, particularly impacting areas such as cancer treatment, autoimmunity, and infectious diseases. The company's notable feature is its advanced proteomic technology platform, which enables the identification and validation of novel target molecules for drug development. In the financial market, Perseus Proteomics Inc. plays a significant role as a pioneering entity in the biopharmaceutical landscape, contributing to the advancement of personalized medicine and tailored treatment strategies. As such, it garners attention from investors interested in cutting-edge medical research and development, holding a place among innovative firms dedicated to transforming healthcare outcomes.

CEOMr. Takuya Yokokawa

Websitehttps://www.ppmx.com

SectorHealthcare

IndustryDrug Manufacturers - General

Employees32

Company Statistics

FY 2025

Profile

¥2,040,488,307Market Cap

¥120,375,000Revenue

0.00Shares Out

32Employees

Margins

86.44%Gross

-623.95%EBITDA

-686.55%Operating

-749.61%Pre-Tax

-751.65%Net

Valuation

-2.26P/E

1.42P/B

16.95EV/Sales

-0.50EV/EBITDA

-2.57P/FCF

Growth (CAGR)

18.72%Rev 3Yr

7.02%Rev 5Yr

N/AOp Inc 3Yr

N/AOp Inc 5Yr

N/ANet Inc 3Yr

N/ANet Inc 5Yr

Returns

-51.52%ROA

-63.93%ROE

-47.05%ROIC

Financial Health

¥1,667,921,000Cash & Cash Equivalents

¥-1,281,491,000Net Debt

26.98%Debt/Equity

N/AInterest Cov

Alpha Chat Insight

“Perseus Proteomics Inc. trades at a P/E of -2.3 (undervalued) with modest ROE of -63.9%. 3Y revenue CAGR of 18.7% highlights clear growth momentum.”

Ask for details →

Frequently Asked Questions

Perseus Proteomics Inc. (ticker: 4882) is a company listed on JPX in the Healthcare sector (Drug Manufacturers - General). It has approximately 32 employees. Market cap is $2.0B.

The current price is 143 with a P/E ratio of -2.26x and P/B of 1.42x.

ROE is -63.93% and operating margin is -686.55%. Annual revenue is $120M.